• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8/13/24 4:30:19 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email
    8-K
    0001369290false00013692902024-08-092024-08-09

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 9, 2024

    Myomo, Inc.

    (Exact Name of Company as Specified in Charter)

     

     

     

     

     

    Delaware

     

    001-38109

     

    47-0944526

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

     

    137 Portland St., 4th Floor

    Boston, MA

     

    02114

    (Address of Principal Executive Offices)

     

    (Zip Code)

    Company’s telephone number, including area code: (617) 996-9058

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

     

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share

     

    MYO

     

    NYSE American

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


    Item 1.01. Entry into a Material Definitive Agreement.

    On August 9, 2024, Myomo, Inc. (the “Company”) entered into a lease with NDB Property Owner 1, L.P. (the “Landlord”), for approximately 36,208 square feet of office, research and development and light manufacturing space located in Burlington, MA (the “Lease”). The space will serve as the Company’s new corporate headquarters and manufacturing facility, which the Company expects to begin occupying by the end of 2024.

    The Lease is subject to fixed monthly rent, commencing six months after the Landlord delivers the initial 28,705 square feet of space, expected on November 15, 2024. The remaining 7,503 square feet is expected to be available for occupancy after June 1, 2025. Under the terms of the Lease, rent will be $96,250 per month for the first year of the Lease; $98,542 per month for months 13 – 18; $125,417 per month for months 19 – 24; $128,333 per month for year 3 of the Lease; $135,780 per month for year 4 of the Lease; $138,797 per month for year 5 of the Lease; $141,815 per month for year 6 of the Lease; $144,832 per month for year 7 of the Lease; and $147,849 per month for year 8 of the Lease. In addition to fixed rent, the Company must also pay its ratable share of taxes, maintenance and other operating expenses. The term of the Lease is approximately 88 months following the rent commencement date. The Company has the option to extend the Lease for an additional five years, subject to certain conditions being satisfied. The Lease also includes a tenant improvement allowance of $700,000. In connection with the signing of the Lease, the Company issued a letter of credit for $375,000 to the Landlord, which is cash collateralized in the same amount.

    The foregoing description of the terms of the Lease does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    Item 2.03 Creation of a Direct Financial Obligation.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference into this Item 2.03.

     

    Item 9.01.

    (d) Exhibits

    Exhibit
    No.

     

    Description

    10.1

     

    Lease Agreement, dated August 9, 2024, by and between the Registrant and NDB Property Owner 1. L.P.

     

     

     

    104

     

    Cover page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

    MYOMO, INC.

     

     

     

     

    Date:

    August 13, 2024

    By:

    /s/ David A. Henry

     

     

     

    David A. Henry
    Chief Financial Officer


    Get the next $MYO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gudonis Paul R was granted 11,637 shares, increasing direct ownership by 0.93% to 1,260,650 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    1/14/26 4:20:20 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Chief Financial Officer Henry David A was granted 8,727 shares, increasing direct ownership by 2% to 436,627 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    1/14/26 4:19:07 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    SEC Filings

    View All

    SEC Form S-8 filed by Myomo Inc.

    S-8 - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:49:09 PM ET
    $MYO
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by Myomo Inc.

    10-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:16:01 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MYOMO, INC. (0001369290) (Filer)

    3/9/26 4:10:25 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Myomo with a new price target

    Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    7/31/24 7:20:07 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Lake Street initiated coverage on Myomo with a new price target

    Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

    5/20/24 9:00:38 AM ET
    $MYO
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Myomo with a new price target

    H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

    12/15/23 8:26:14 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced today it has entered into its first among a series of expected network participation agreements with Elevance Health. The contracts, which include the Anthem-affiliated Commercial, Medicare Advantage, and Medicaid plans are expected to become effective on a market-by-market basis through the second quarter of 2026. Once complete, the addition of these 45 million medical members will bring Myomo's total number of covered lives under commercial insurance plans to over 80 million. These a

    3/9/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $5,355 worth of shares (7,437 units at $0.72), increasing direct ownership by 2% to 481,857 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/24/25 4:04:45 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Crowley Thomas Aloysius Jr. bought $3,233 worth of shares (4,385 units at $0.74), increasing direct ownership by 6% to 75,748 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    11/21/25 7:22:22 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Director Kirk Thomas F bought $57,500 worth of shares (50,000 units at $1.15), increasing direct ownership by 12% to 474,420 units (SEC Form 4)

    4 - MYOMO, INC. (0001369290) (Issuer)

    8/26/25 8:10:16 AM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    10/18/24 2:21:35 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/12/24 10:35:49 AM ET
    $MYO
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by Myomo Inc.

    SC 13G/A - MYOMO, INC. (0001369290) (Subject)

    7/11/24 6:02:07 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Financials

    Live finance-specific insights

    View All

    Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter revenue of $11.4 million, full year revenue of $40.9 million 42% of fourth quarter revenue from recurring patient sources Record 241 authorizations and orders in the quarter Introduces 2026 revenue guidance of $43 million to $46 million as Company emphasizes recurring sources of revenue Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2025. "We delivered 2025 revenue at the midpoint of o

    3/9/26 4:06:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo to Report Fourth Quarter 2025 Financial Results on March 9

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2025 on Monday, March 9, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after

    3/2/26 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    Myomo Reports Third Quarter 2025 Financial and Operating Results

    Revenue of $10.1 million 229 authorizations and orders, highest number this year Reiterates full year revenue guidance of $40 million to $42 million Conference call begins today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decrease

    11/10/25 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Myomo Appoints Heather Getz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

    3/28/24 4:05:00 PM ET
    $BFLY
    $MYO
    Medical Electronics
    Health Care
    Industrial Specialties

    Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

    1/30/23 4:05:00 PM ET
    $MYO
    Industrial Specialties
    Health Care